Impact of IL1RN variants on response to interleukin-1 blocking therapy in systemic juvenile idiopathic arthritis.
To analyze the reported association of IL1RN polymorphisms with response to IL-1 blockade in a German cohort of patients with systemic idiopathic arthritis (SJIA) and to assess other factors on treatment response. Sixty-one patients with SJIA who had received IL-1 blockade were identified within the German Autoinflammatory Disease (AID) registry and DNA biobank. Response to IL-1 blockade was assessed by (1) clinical response (at least initial response compared to poor response), (2) switch to anti-IL-6 receptor therapy following IL-1 blockade or not (3) clinically inactive disease within 6 months of IL-1 blockade, (4) modified juvenile disease activity score and (5) reaching of a glucocorticoid free state. Basic demographic data, key features of the disease course, laboratory data, and IL1RN single nucleotide polymorphisms (SNPs) were assessed. Six out of 7 IL1RN SNPs reported to be associated with response to anakinra therapy were analyzed. These 6 IL1RN SNPs were inherited as haplotypes. We could not confirm an association of IL1RN haplotypes and SNPs with response to IL-1 blockade. Patients who received tocilizumab therapy following IL-1 blockade had a longer duration from disease onset to diagnosis than those who did not (median 0.27 years to 0.08 years). In this study, we could not confirm an impact of IL1RN SNPs on response to therapy with anakinra or canakinumab in a cohort of patients with SJIA. However, we observed that a longer timeframe from onset to diagnosis was associated with a poorer long-term treatment response, supporting the "window of opportunity" hypothesis.